New Drugs and New Indications

[Guest guest]

These drugs probably won't be on the market for quite some time but

it's good to know that the future looks promising.

http://www.eplab.com/eplab/displayArticle.cfm?articleID=article2673

The following is a review of some of the new drug formulations which

are thought to be promising.

AMIODORONE. an aqueous version of amiodrone

AZIIMILIDE was studied extensively in the ALIVE trial and found to

have no effect on survival; however, the rate of atrial fibrillation

in the participants was decreased due to the drug's ability to

maintain sinus rhythm.

DRONRDARONE is a benzofuran derivative of amiodarone, which is being

tested for maintenance of sinus rhythm in patients with a history of

atrial fibrillation.

DTI-0009 is an adenosine receptor blocker that has been used to

control ventricular response in atrial fibrillation.

TECADENOSON (CVT-510) is an adenosine receptor blocker which, unlike

adenosine, appears to terminate AV node dependent supraventricular

tachycardias without the hypotension and bronchoconstriction.

TEDISAMIL (KC-8857) was originally developed as an antianginal agent.

Its antiarrhythmic properties involve a blockade of multiple

potassium currents, resulting in a lengthening on the monophasic

action potential and refractory periods in the atrium and a decrease

in atrial pacing rates.

Conclusion:

The future holds great promise for some exciting new drugs to treat

what seems to be electrophysiology's last great frontiers.

http://www.eplab.com/eplab/displayArticle.cfm?articleID=article2673

[Guest guest]

P:

Thanks for the great summary and fantastic URL.

- Ou alum in MI

[Guest guest]

P:

Thanks for the great summary and fantastic URL.

- Ou alum in MI

[Guest guest]

P:

Thanks for the great summary and fantastic URL.

- Ou alum in MI